The OncLive® Conference page includes a listing of all conferences covered by OncLive®, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.
October 12th 2021, 7:56pm
Susan Tsai, MD, MHS, discusses ongoing research efforts being made in the realm of pancreatic cancer.
September 23rd 2021, 2:00pm
The addition of bevacizumab to erlotinib continued to provide a significant progression-free survival benefit over erlotinib alone when used in the frontline treatment of patients with EGFR-mutated, nonsquamous non–small cell lung cancer, according to data from the final analysis of the phase 3 BEVERLY trial.
September 22nd 2021, 7:00pm
Regorafenib did not show a benefit with progression-free survival in patients with advanced or metastatic chordoma.
September 22nd 2021, 3:10pm
Treatment with acalabrutinib as monotherapy or in combination with obinutuzumab improved quality-adjusted survival compared with chlorambucil plus obinutuzumab in patients with treatment-naïve chronic lymphocytic leukemia.
September 21st 2021, 10:05pm
The median real-world progression-free survival with durvalumab was higher compared with the median progression-free survival reported in the durvalumab arm of the phase 3 PACIFIC trial in patients with stage III non–small cell lung cancer.
September 21st 2021, 9:40pm
Fam-trastuzumab deruxtecan-nxki led to improved responses in patients with higher HER2 expression at baseline, whereas responses were seen irrespective of RAS- and PIK3CA mutation status and blood tumor mutational burden levels in patients with HER2-positive, metastatic colorectal cancer.
September 21st 2021, 9:37pm
Meghan Thompson, MD, discusses the results of the phase 1/2 BRUIN study in patients with Richter transformation.
September 21st 2021, 9:30pm
Tadeusz Robak, MD, PhD, discusses the results of the 7-year follow-up analysis of the phase 3 RESONATE-2 trial in chronic lymphocytic leukemia.
September 21st 2021, 7:27pm
Adavosertib demonstrated a 65% reduction in the risk of disease progression or death compared with active monitoring in patients with TP53-/RAS-mutant metastatic colorectal cancer following first-line chemotherapy.
September 21st 2021, 5:11pm
The addition of durvalumab to platinum/etoposide chemotherapy continued to demonstrate an overall survival benefit over chemotherapy alone with a favorable safety profile in patients with extensive-stage small cell lung cancer.
September 21st 2021, 3:50pm
Giredestrant resulted in a greater relative reduction in Ki67 score from baseline to week 2 of a window of opportunity phase vs anastrozole in patients with estrogen receptor–positive, HER2-negative early breast cancer, according to results from an interim analysis of the phase 2 coopERA Breast Cancer trial.
September 21st 2021, 3:29pm
Personalized medicine has come to the forefront of breast cancer management, with genomic tools being utilized to avoid unnecessary chemotherapy in those with early-stage disease, PARP and PI3K inhibitors improving outcomes for those who harbor select mutations, and the emergence of highly active targeted agents shaking up the HER2-positive paradigm.
September 21st 2021, 2:24pm
During the XIX International Workshop on Chronic Lymphocytic Leukemia, which occurred virtually 17-20 September, Dr. John Byrd was presented the Binet-Rai Medal Award for his outstanding findings, which led to the use of BTK Inhibitors in almost every phase of CLL therapy.
September 21st 2021, 1:14pm
Sitravatinib, a spectrum-selective TKI targeting TAM receptors and VEGFR2, administered in combination with nivolumab induced durable response and robust survival outcomes for patients with non-small cell lung cancer who progressed after deriving benefit from treatment with a checkpoint inhibitor and/or platinum doublet chemotherapy.
September 21st 2021, 1:14pm
Blood-based tumor mutational burden does not predict a benefit of first-line atezolizumab over chemotherapy in patients with non–small cell lung cancer.
September 20th 2021, 10:10pm
The triplet combination of umbralisib, ublituximab, and pembrolizumab demonstrated durable responses with a tolerable safety profile in patients with relapsed/refractory chronic lymphocytic leukemia and Richter’s transformation.
September 20th 2021, 9:42pm
Andre H. Goy, MD, discusses the importance of refined decision making with precision medicine.
September 20th 2021, 9:37pm
John L. Marshall, MD, discusses the importance of molecular profiling when utilizing precision medicine.
September 20th 2021, 9:25pm
Benjamin P. Levy, MD, discusses potential strategies to overcome resistance to osimertinib in EGFR-mutant non–small cell lung cancer.
September 20th 2021, 9:23pm
William G. Wierda, MD, PhD, discusses the fixed-duration cohort results of the phase 2 CAPTIVATE trial in chronic lymphocytic leukemia.